Future oncology最新文献

{"title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study.","authors":"Shanu Modi","doi":"10.1080/14796694.2024.2434388","DOIUrl":"10.1080/14796694.2024.2434388","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"367-380"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avelumab maintenance treatment for advanced urothelial cancer: plain language summary of long-term results from the JAVELIN Bladder 100 study.","authors":"Thomas Powles, Se Hoon Park, Howard Gurney, Yohann Loriot, Srikala S Sridhar, Joaquim Bellmunt, Alessandra di Pietro, Petros Grivas","doi":"10.1080/14796694.2024.2435208","DOIUrl":"10.1080/14796694.2024.2435208","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"381-391"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing fruquintinib with placebo for treating patients with previously treated metastatic colorectal cancer: a plain language summary of the FRESCO-2 study.","authors":"Arvind Dasari, Sara Lonardi, Brian MacLeod, Suzanne McPeak, Josep Tabernero, Cathy Eng","doi":"10.1080/14796694.2024.2425568","DOIUrl":"10.1080/14796694.2024.2425568","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"281-292"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study.","authors":"Giannis Mountzios, Sofia Lampaki, Helena Linardou, Vassilis Georgoulias, Dimitrios Mavroudis, Stavros Anevlavis, Andriani Charpidou, Maria Lykka, Dionysis Spyratos, Evangelos G Sarris, Alvertos Somarakis, Christina Papista, Alexandros Glentis, Aristeidis Nikolaou, Zoe Paparepa, Foteini Papageorgiou, Konstantinos N Syrigos","doi":"10.1080/14796694.2024.2442295","DOIUrl":"10.1080/14796694.2024.2442295","url":null,"abstract":"<p><strong>Background: </strong>The treatment landscape of non-metastatic non-small cell lung cancer (NM-NSCLC) is rapidly evolving with recent approvals of immunotherapies and targeted therapies.</p><p><strong>Methods: </strong>This retrospective study included 202 adults diagnosed with NM-NSCLC between 1 January 2018 and 31 December 2020 primarily aiming to capture initial management strategies.</p><p><strong>Results: </strong>Most frequent treatment patterns among Stage I/II patients (<i>N</i> = 84) were surgery only (48.8%) and surgery with adjuvant chemotherapy (with/without RT; 42.9%). Among Stage III patients (<i>N</i> = 118), most frequent patterns were chemotherapy plus radiotherapy (44.9%) and chemotherapy only (18.6%); 58.6% of Stage IIIA patients underwent surgery (of these, 32.4% also received chemotherapy and radiotherapy).</p><p><strong>Conclusion: </strong>Initial strategy was aligned with contemporary at that time European guidelines, setting a benchmark for understanding the future uptake of new therapies.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"447-462"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey.","authors":"Raquel Aguiar-Ibáñez, Kelly McQuarrie, Sayeli Jayade, Hannah Penton, Laura DiGiovanni, Rutika Raina, Marieke Heisen, Ana Martinez","doi":"10.1080/14796694.2024.2436342","DOIUrl":"10.1080/14796694.2024.2436342","url":null,"abstract":"<p><strong>Background: </strong>Following an early-stage cancer diagnosis, recurrences can occur. To quantify financial impacts of a first recurrence, we surveyed patients and caregivers.</p><p><strong>Methods: </strong>The survey was self-administered online to patients (<i>N</i> = 202) with early-stage bladder, gastric, head and neck, melanoma, non-small cell lung, renal cell, and triple-negative breast cancers that recurred and caregivers (<i>N</i> = 100) of such patients. Work productivity and financial impacts were explored.</p><p><strong>Results: </strong>Negative impacts on work productivity, employment, finances, and healthcare resource use were identified, with significant differences seen across cancer types, between locoregional and distant/metastatic recurrences, and from pre-recurrence to post-recurrence.</p><p><strong>Conclusions: </strong>The financial burden to patients, caregivers, healthcare systems, and society following early-stage cancer recurrence is substantial. Treatments that decrease recurrences can reduce this burden.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"349-365"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.","authors":"Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Haibo Wang, Yongmei Yin, Xiaojia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shusen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yiding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yueyin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan","doi":"10.1080/14796694.2024.2430106","DOIUrl":"10.1080/14796694.2024.2430106","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"421-429"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A simplified scoring system for predicting treatment response in limited-stage small-cell lung cancer (EAST score).","authors":"Yu Ito, Yoshitaka Zenke, Tetsuya Sakai, Yuji Shibata, Hiroki Izumi, Kaname Nosaki, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Masaki Nakamura, Hidehiro Hojo, Takehiro Izumo, Koichi Goto","doi":"10.1080/14796694.2024.2444858","DOIUrl":"10.1080/14796694.2024.2444858","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed at developing a scoring system (EAST score) to predict recurrence after chemoradiotherapy in limited-stage small-cell lung cancer (LS-SCLC).</p><p><strong>Patients & methods: </strong>Treatment-naïve LS-SCLC patients receiving concurrent chemoradiotherapy (CCRT) (<i>N</i> = 234) or sequential chemoradiotherapy (<i>N</i> = 53) were retrospectively reviewed. Using data from CCRT population, clinical and radiological variables associated with disease progression were identified. Selected variables were assigned numerical scores based on their estimated hazard ratios (HRs), and the EAST score was established.</p><p><strong>Results: </strong>EAST score incorporated N3 disease and serum biomarkers (lactate dehydrogenase, pro-gastrin-releasing peptide, and cytokeratin-19 fragment). In the CCRT population, progression-free survival (PFS) was significantly shorter in the high-risk group (EAST score ≥ 2) than the low-risk group (EAST score ≤ 1) (median, 9.4 months vs. 20.6 months; HR [95% confidence interval (CI)], 2.09 [1.50-2.91]). As for the model performance, the 1- and 2-year area under the curve values for PFS were 0.68 and 0.65, respectively. Overall survival was also shorter in the high-risk group (HR [95% CI], 1.49 [1.02-2.16]). Similar trends were observed in the sequential chemoradiotherapy population (HR for PFS [95% CI], 2.43 [1.07-5.53]).</p><p><strong>Conclusions: </strong>EAST score effectively predicts recurrence risk in LS-SCLC, demonstrating the necessity for developing new treatment strategies for high-risk patients.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"473-481"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study.","authors":"Mehdi Hamadani, Paolo F Caimi, Brian Hess, John Radford, Melhem Solh, Pier Luigi Zinzani, Luqiang Wang, Zhiying Cindy Xu, Carmelo Carlo-Stella","doi":"10.1080/14796694.2024.2418747","DOIUrl":"10.1080/14796694.2024.2418747","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This article provides a plain-language summary of the results of a clinical trial called the LOTIS-2 study.The LOTIS-2 study included 145 participants with an aggressive type (one that forms, grows, or spreads quickly) of non-Hodgkin lymphoma called diffuse large B-cell lymphoma (a type of blood cancer), or DLBCL for short, whose disease came back or did not respond after 2 or more previous treatments. The LOTIS-2 study was conducted from August 2018 to September 2022.Participants received loncastuximab tesirine, also referred to as Lonca, for up to 1 year, or longer if the treatment was working, and their health was monitored. The primary purpose of the LOTIS-2 study was to find out if participants' lymphoma shrank partially or completely after receiving Lonca.</p><p><strong>What were the results?: </strong>A total of 145 participants who were treated with Lonca lived a median (meaning the middle value in a set of numbers) of 9.5 months after starting Lonca treatment. The lymphoma shrank partially or completely in nearly half of participants and shrank completely in 1 in 4 participants. Among participants whose disease either shrank partially or completely in response to Lonca treatment, responses happened relatively quickly, with a median time to response (the time between starting treatment and when the participant's lymphoma either partially or completely shrank) of 41 days. In these participants, the lymphoma did not grow or come back for a median of 13.4 months. Researchers estimated that 83% of participants whose disease shrank completely remained disease free for at least 1 year.Nearly all participants had a side effect from Lonca treatment. The most common side effects were abnormal liver tests (increased gamma-glutamyl transferase), decreased white blood cells (neutropenia), and decreased platelets (thrombocytopenia). One in 4 participants had their treatment stopped due to side effects. The most common side effects that resulted in participants needing to stop Lonca treatment were abnormal liver tests (increased gamma-glutamyl transferase), swelling in the arms or legs (peripheral edema), swelling in an individual spot (localized edema), and fluid around the lungs (pleural effusion).</p><p><strong>What do the results of the study mean?: </strong>These results show that Lonca is a treatment option with controllable side effects for many patients with DLBCL whose disease did not respond or came back after 2 or more previous treatments. For participants whose lymphoma completely shrank while taking Lonca, those responses to treatment occurred quickly and lasted for over a year.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"261-270"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success.","authors":"Ashton Hunt, Daria Ditri, Ankit Chadha, Georgina Keogh, Jack Thompson, Will Loughborough, Iain McNeish, Jonathan Krell, Jacqueline McDermott, Laura Tookman, Sadaf Ghaem-Maghami","doi":"10.1080/14796694.2024.2433412","DOIUrl":"10.1080/14796694.2024.2433412","url":null,"abstract":"<p><strong>Introduction: </strong>Testing for tumor BRCA mutations and homologous recombination deficiency (HRD) is recommended for all patients with advanced high-grade epithelial ovarian cancer. Delays in the HRD testing process can significantly affect the treatment offered to patients.</p><p><strong>Methods: </strong>HRD testing pathways and sampling processes were analyzed for tests sent from a tertiary gynae-oncology referral center between December 2020 and January 2023.</p><p><strong>Results: </strong>A total of 148 hRD tests were performed in 125 patients. The overall success rate of HRD testing was 69.6%. The success rates of obtaining results were: from diagnostic image-guided biopsy 66.7% (<i>n</i> = 40/60), at primary surgery 91.5% (<i>n</i> = 42/47), and at interval debulking surgery 51.2% (<i>n</i> = 21/41). The use of a larger 16-gauge needle used at image-guided biopsy produced a 100% success rate. Of 148 tests carried out, the median time for result was 28 days (range 14-158 days), with only 27% returned results in 21 or fewer days. In successful tests, 44.7% were classified as HRD-positive. 97% of patients with HRD-positive tumors treated at the center received a PARP inhibitor as part of their first-line maintenance treatment.</p><p><strong>Conclusions: </strong>By optimizing the factors affecting HRD test success, we can obtain faster results and offer patients appropriate treatment at earlier time points to improve patient outcomes.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"341-347"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States.","authors":"Tammy A Schuler, Shital Kamble, Kaushal Desai, Emily Bland, Leonid Dubrovsky, Bruce Feinberg","doi":"10.1080/14796694.2024.2444874","DOIUrl":"10.1080/14796694.2024.2444874","url":null,"abstract":"<p><strong>Introduction: </strong>Given treatment landscape changes, understanding the prevalence of medical conditions/comorbidities influencing real-world unresectable hepatocellular carcinoma (uHCC) treatment decisions is key for improving outcomes.</p><p><strong>Patients and methods: </strong>In a retrospective chart review, physicians abstracted data from uHCC patients initiating first-line treatment (1L) between June 2020 and April 2022. Frequencies of medical conditions/comorbidities at 1L initiation were reported.</p><p><strong>Results: </strong>Among 433 patients, 77% had Barcelona Cancer Liver Clinic (BCLC)-C and 37% had Child-Pugh B status. Overall, 51% had ≥ 1 condition/comorbidity making them potentially less suitable for a 1L immunotherapy combination regimen (e.g. atezolizumab plus bevacizumab), including upper/lower gastrointestinal bleeding risk (38%), chronic kidney disease (15%), history of thromboembolic events (12%), and autoimmune disorders (5%).</p><p><strong>Discussion: </strong>More than half of the patients had ≥ 1 medical condition/comorbidity making them potentially less suitable for a 1L immunotherapy combination. This study provides timely insight into how immunotherapy combinations are being used in the real-world setting among a large number of patients.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"313-319"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}